RHYTHM PHARMACEUTICALS, INC. (RYTM)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, RHYTHM PHARMACEUTICALS, INC. reported revenue of $189.76M, up 45.8% from the prior year. The company ran a net loss, with a net margin of -103.6%. It held $480.20M in total assets against $210.17M in total liabilities.
Key ratios (FY2025)
-101.2%
Operating margin
-103.6%
Net margin
-141.3%
Return on equity
+45.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $189.76M | $130.13M | $77.43M | $23.64M | $3.15M | — | — | — | — | — |
| Cost of Revenue | $19.49M | $13.37M | $9.30M | $2.13M | $599.0K | — | — | — | — | — |
| Operating Income | -$192.02M | -$265.50M | -$184.36M | -$179.16M | -$170.06M | -$136.57M | -$146.00M | -$78.42M | -$32.41M | -$25.91M |
| Net Income | -$196.54M | -$260.60M | -$184.68M | -$181.12M | -$69.61M | -$134.00M | -$140.73M | -$74.06M | -$33.71M | -$25.87M |
| EPS (Diluted) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 | $-3.86 | — | — | — |
| Total Assets | $480.20M | $392.27M | $332.75M | $382.48M | $329.52M | $187.07M | $308.52M | $260.21M | $151.74M | $12.34M |
| Total Liabilities | $210.17M | $227.72M | $162.99M | $118.22M | $45.37M | $20.55M | $27.50M | $13.95M | $6.95M | $5.04M |
| Shareholders' Equity | $139.07M | $21.73M | $169.76M | $264.26M | $284.15M | $166.53M | $281.02M | $246.26M | $144.79M | -$32.70M |
| Cash & Equivalents | $54.30M | $89.14M | $60.08M | $127.68M | $59.25M | $100.85M | $62.29M | $49.54M | $34.24M | $6.54M |
| Operating Cash Flow | -$115.67M | -$113.88M | -$136.16M | -$173.43M | -$146.00M | -$121.98M | -$122.75M | -$62.06M | -$29.46M | -$23.22M |
| Capital Expenditures | $953.0K | $0 | $47.0K | $281.0K | $434.0K | $214.0K | $3.38M | $722.0K | $133.0K | $1.06M |
| Shares Outstanding | 67.21M | 62.39M | 59.43M | 56.61M | 50.28M | 44.24M | 44.00M | 34.41M | 27.28M | 10.20M |